Follicular mucinosis associated with early stage cutaneous T-cell lymphoma: successful treatment with interferon alpha-2b and acitretin

被引:0
作者
Kontochristopoulos, GJ
Exadaktylou, D
Hatziolou, E
Tassidou, A
Zakopoulou, N
机构
[1] A Syngros Hosp, Dept Dermatol 2, Athens 16121, Greece
[2] A Syngros Hosp, Dept Pathol, Athens 16121, Greece
[3] Evangelismos Med Ctr, Dept Hematopathol, Athens, Greece
关键词
acitretin; cutaneous T-cell lymphoma; follicular mucinosis; interferon alpha-2b;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND: Follicular mucinosis (FM) is a rare dermatosis characterized by mucin deposits in the pilosebaceous units. It is divided into a primary-benign type and a secondary type associated mostly with lymphomas. No standard effective therapy is available for the primary FM while in the secondary form treatment is aimed against the underlying disease. METHODS: We report a case of secondary FM in which a cutaneous T-cell lymphoma was detected 6 years after the initial eruption. RESULTS: Complete remission was achieved with combination therapy of interferon alpha-2b at a dose of 6 million U subcutaneously three times a week, and acitretin 35 mg/day, for 6 months. CONCLUSION: Regular clinical and histopathological evaluation is suggested for all patients with FM. For cases associated with cutaneous T-cell lymphoma the combination of interferon alpha and acitretin seems to be a good therapeutical approach.
引用
收藏
页码:117 / 121
页数:5
相关论文
共 26 条
  • [21] Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma
    Fierro, M
    Doveil, GC
    Quaglino, P
    Savoia, P
    Verrone, A
    Bernengo, MG
    DERMATOLOGY, 1997, 194 (03) : 268 - 272
  • [22] Successful Implementation of a Rural Extracorporeal Photopheresis Program for the Treatment of Cutaneous T-cell Lymphoma and Chronic Graft-Versus-Host Disease in a Rural Hospital
    Weber, Litchia L.
    Dunbar, Nancy M.
    Meehan, Kenneth R.
    Szczepiorkowski, Zbigniew M.
    Lansigan, Frederick
    JOURNAL OF CLINICAL APHERESIS, 2015, 30 (06) : 359 - 363
  • [23] Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting
    Peacock, Adrian
    Dehle, Francis
    Zapata, Oscar Alejandro Mesa
    Prince, H. Miles
    Gennari, Francesca
    Taylor, Colman
    VALUE IN HEALTH, 2022, 25 (06) : 965 - 974
  • [24] Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints
    Rupoli, Serena
    Goteri, Gaia
    Morsia, Erika
    Torre, Elena
    Giantomassi, Federica
    Campanati, Anna
    Offidani, Anna Maria
    Molinelli, Elisa
    Brandozzi, Giuliano
    Serresi, Stefano
    Giacchetti, Alfredo
    Bugatti, Leonardo
    Filosa, Giorgio
    Mozzicafreddo, Giorgio
    Simonacci, Marco
    Olivieri, Attilio
    DERMATOLOGIC THERAPY, 2022, 35 (10)
  • [25] Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201)
    Hamada, Toshihisa
    Tokura, Yoshiki
    Sugaya, Makoto
    Ohtsuka, Mikio
    Tsuboi, Ryoji
    Nagatani, Tetsuo
    Kiyohara, Eiji
    Tani, Mamori
    Setoyama, Mitsuru
    Matsushita, Shigeto
    Kawai, Kazuhiro
    Yonekura, Kentaro
    Saida, Toshiaki
    Iwatsuki, Keiji
    JOURNAL OF DERMATOLOGY, 2019, 46 (07) : 557 - 563
  • [26] IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma
    Van Der Weyden, Carrie
    Bagot, Martine
    Neeson, Paul
    Darcy, Phil K.
    Prince, H. Miles
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (08) : 691 - 697